

(12) **United States Patent**
Naicker et al.

(10) **Patent No.:** US 6,613,739 B1
(45) **Date of Patent:** Sep. 2, 2003

(54) **DEUTERATED CYCLOSPORINE ANALOGS
AND THEIR USE AS
IMMUNOMODULATING AGENTS**

4,703,033 A 10/1987 Seebach
4,727,018 A 2/1988 Eichner et al.

(List continued on next page.)

(75) Inventors: **Selvaraj Naicker**, Edmonton (CA);
Randall W. Yatscoff, Edmonton (CA);
Robert T. Foster, Edmonton (CA)

FOREIGN PATENT DOCUMENTS

EP 0 283 801 9/1988
EP 0 373 260 6/1990
EP 0 557 544 1/1994
WO WO9526325 10/1995

(73) Assignee: **Isotechnika, Inc.**, Edmonton (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

OTHER PUBLICATIONS

Curran, D., et al. "Intramolecular Hydrogen Transfer Reactions of o-(Bromophenyl)dialkylsilyl Ethers. Preparation of Rapamycin-d₁" *Tetrahedron Letters*. 33(17):2295-2298 (1992).

Eberle, M. K., et al. "Modifications of the MeBmt Side Chain of Cyclosporin A." *Bioorganic & Medicinal Chemistry Letters*. 5(15):1725-1728 (1995).

(List continued on next page.)

(21) Appl. No.: **09/634,945**

(22) Filed: **Aug. 7, 2000**

Related U.S. Application Data

(63) Continuation of application No. 09/184,109, filed on Nov. 2, 1998.

(51) **Int. Cl.⁷** **A61K 38/00**

(52) **U.S. Cl.** **514/11; 530/321; 530/350;**
530/363; 530/806; 530/807

(58) **Field of Search** 514/11; 530/321,
530/350, 363, 806, 807

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,108,985 A 8/1978 Rügger et al. 514/11
4,117,118 A 9/1978 Härrä et al.
4,201,771 A 5/1980 Onishi et al.
4,210,581 A 7/1980 Rügger et al.
4,220,641 A 9/1980 Traber et al.
4,288,431 A 9/1981 Traber et al.
4,384,996 A 5/1983 Bollinger et al.
4,396,542 A 8/1983 Wenger 530/321
4,404,194 A 9/1983 Arala-Chaves
4,554,351 A 11/1985 Wenger 544/177
4,639,434 A 1/1987 Wenger et al. 544/11
4,681,754 A 7/1987 Siegl

Primary Examiner—Brenda Brumback

Assistant Examiner—Anish Gupta

(74) *Attorney, Agent, or Firm*—Burns Doane Swecker & Mathis LLP

(57) **ABSTRACT**

Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives.

16 Claims, 4 Drawing Sheets

U.S. PATENT DOCUMENTS

4,764,503 A 8/1988 Wenger 514/11
 4,765,980 A 8/1988 DePrince et al.
 4,771,122 A 9/1988 Seebach
 4,798,823 A 1/1989 Witzel 514/11
 4,839,342 A 6/1989 Kaswan
 4,885,276 A 12/1989 Witzel 514/11
 4,914,188 A 4/1990 Dumont et al. 530/317
 4,963,362 A 10/1990 Rahman et al.
 4,996,193 A 2/1991 Hewitt et al.
 4,997,648 A 3/1991 Galpin et al.
 5,013,719 A 5/1991 Bowlin
 5,051,402 A 9/1991 Kurihara et al.
 5,079,341 A 1/1992 Galpin et al. 530/321
 5,116,816 A 5/1992 Dreyfuss et al. 514/11
 5,122,511 A 6/1992 Patchett et al. 514/11
 5,214,130 A 5/1993 Patchett et al. 530/33
 5,227,467 A 7/1993 Durette 530/321
 5,236,899 A 8/1993 Durette 514/11
 5,239,057 A 8/1993 Wang et al. 530/321
 5,256,547 A 10/1993 Rudat et al.
 5,284,826 A 2/1994 Eberle 514/11
 5,318,901 A 6/1994 Patchett et al.
 5,342,625 A 8/1994 Hauer et al. 424/455
 5,350,574 A 9/1994 Erlanger et al. 514/9
 5,382,655 A 1/1995 Szanya et al.
 5,389,382 A 2/1995 List et al.
 5,401,649 A 3/1995 Davalian et al.
 5,405,785 A 4/1995 Erlanger et al. 436/531
 5,409,816 A 4/1995 Lundell et al.
 5,411,952 A 5/1995 Kaswan
 5,427,960 A 6/1995 Wang et al. 436/536
 5,489,668 A 2/1996 Morrison et al.
 5,525,590 A * 6/1996 Bollinger et al. 514/11
 5,540,931 A 7/1996 Hewitt et al.
 5,616,595 A 4/1997 Chu et al.
 5,624,902 A 4/1997 Blondelle et al.
 5,639,724 A 6/1997 Cavanak
 5,639,852 A 6/1997 Rich et al. 530/317

5,643,870 A 7/1997 Boelsterli et al. 514/11
 5,709,797 A 1/1998 Bocchiola et al.
 5,741,512 A 4/1998 Hauer et al. 424/450
 5,741,775 A 4/1998 Balkovec et al.
 5,747,330 A 5/1998 Casareto et al.
 5,767,069 A 6/1998 Ko et al. 514/11

OTHER PUBLICATIONS

Hensens, O., et al. "The Preparation of [2-Deutero-3-Fluoro-D-ALA⁸] Cyclosporin A By Directed Biosynthesis." *J. Antibiotics*. 45(1): 133-135 (1992).

Hughes, P. et al. "The Isolation, Synthesis and Characterization of An Isomeric Form of Rapamycin." *Tetrahedron Letters*. 33(33): 4739-4742 (1992).

Park, S.B., et al. "A Semi-Synthetic Approach to Olefinic Analogs of Amino Acid One (MeBMT) in Cyclosporin A." *Tetrahedron Letters*, 30, 32, 4215-4218 (1989).

Patchett, A., et al. "Analogues of Cyclosporin A Modified at the D-ALA⁸ Position." *J. Antibiotics*. 45(1): 94-102 (1992).
 Seebach, D., et al. "Modification of Cyclosporin A (CS)¹: Generation of an Enolate at the Sarcosine Residue and Reactions with Electrophiles." *Helvetica Chimica Acta*. 76 (1993).

Yohannes, D., et al. "Degredation of Rapamycin: Retrieval of Major Intact Subunits." *Tetrahedron Letters*. 33(49): 7469-7472 (1992).

von Wartberg, A., R. Traber. "Chemistry of the Natural Cyclosporin Metabolites." *Prog. Allergy*. 38 28-45 (1986).

Kobel, H., and R. Traber. "Directed Biosynthesis of Cyclosporins." *European Journal of Applied Microbiology and Biotechnology*. (14) 237-240 (1982);

von Traber, René, et al. "The Structure of Cyclosporin C." *Helvetica Chimica Acta* 60(4) 1247-1255 (1977).

* cited by examiner




Fig. 1




Fig. 2




Fig. 3

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.